

# **Amyloidosis : Recent Trends and Updates in Diagnosis and Treatment**

*Protocol of Essay*

*Submitted for partial fulfillment of Master Degree in  
Dermatology, venereology and Andrology*

by

**Dalia El-Sayed El-Araby Makled**

*M.B.B.Ch*

Under Supervision of

**Prof. Dr. Adel A. Halim Emam**

*Professor of Dermatology, Venereology and Andrology*

*Faculty of Medicine – Ain Shams University*

**Prof. Dr. Heba Mahmoud El-Sayed Diab**

*Professor of Dermatology, Venereology and Andrology*

*Faculty of Medicine – Ain Shams University*

*Faculty of Medicine*

*Ain Shams University*

**2016**

**الداء النشواني: الاتجاهات الحديثة وتحديثات  
من التشخيص والعلاج  
رسالة**

توطئة للحصول على درجة الماجستير في الأمراض  
الجلدية، التناسلية والذكورة

مقدمة من  
الطبيبة / داليا السيد العربي مقلد  
بكالوريوس الطب والجراحة - جامعة عين شمس

**تحت إشراف**

**الأستاذ الدكتور / عادل أحمد حليم إمام**

أستاذ الأمراض الجلدية و التناسلية و الذكورة

كلية الطب – جامعة عين شمس

**الأستاذة الدكتورة / هبة محمود السيد دياب**

أستاذ الأمراض الجلدية و التناسلية و الذكورة

كلية الطب – جامعة عين شمس

كلية الطب  
جامعة عين شمس

٢٠١٦

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا يَعْلمُ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



*First, thanks to ALLAH for helping me to accomplish this work.*

*I would like to express my deepest gratitude and sincerest appreciation to Prof. Dr. Adel A. Halim Emam, Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Ain Shams University, for his guidance, support and supervision throughout the study.*

*I am also much grateful to Prof. Dr. Heba Mahmoud El Sayed Diab, Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Ain Shams University, for her continuous supervision and support.*

*Last but not least I would like to express my deep thanks and gratitude to every member in my Family and my Colleagues for their help and advice, hoping them a good health.*

*Dalia El-Sayed Makled*

## List of Content

Subjects	Page
• List of abbreviation.....	I
• List of figures .....	IV
• List of tables .....	VI
• Introduction.....	1
• Aim of the Study.....	5
• Review of literature.....	
<b>Chapter 1: Historical Developments And Fibrillogenesis.....</b>	<b>6</b>
Historical developments .....	6
Fibillogenesis.....	8
<b>Chapter 2: Classification, Tissue Tropism, Cytotoxicity And</b>	
<b>    Diagnosis Of Amyloidosis.....</b>	<b>14</b>
Amyloidosis classification.....	14
Tissue tropism.....	18
Cytotoxicity .....	20
Tissue dysfunction.....	21
Kidney and urinary tract amyloidosis.....	21
Cardiac amyloidosis.....	22
Amyloidosis of the gastrointestinal tract and liver .....	22
Amyloidosis of the lung.....	22
Peripheral nerve amyloidosis.....	22
Soft tissue and joint amyloidosis .....	23
Cutaneous amyloidosis .....	23
Diagnosis of amyloidosis.....	24
Biopsy .....	24
Stains.....	27
Electron microscopy .....	28
Determination of the type of amyloidosis .....	29
<b>Chapter 3: Cutaneous Amyloidosis and Updates .....</b>	<b>33</b>
Cutaneous amyloidosis .....	33
Cutaneous amyloidosis as a manifestation of systemic	
amyloidosis .....	34
Localized cutaneous amyloidosis .....	41
Keratinic primary localized amyloidosis (kplca):.....	41
Nodular localized primary cutaneous amyloidosis.....	48
Rare variants: .....	51
• bullous variant.....	55

## *✍ List of Contents*

Poikiloderma-like cutaneous amyloidosis .....	60
Rare cases: .....	64
• Amyloidosis of the external auditory canal (eac).64	
• Primary cutaneous amyloidosis of the genitalia...65	
Secondary amyloidosis associated with various disorders67	
Health-related quality of life in patients with primary cutaneous amyloidosis .....	70
Pruritus.....	70
Treatment .....	71
• <b>Summary .....</b>	<b>113</b>
• <b>References.....</b>	<b>118</b>
• <b>Arabic summary.....</b>	<b>-</b>

## List of Abbreviations

<b>5-HT</b>	5-hydroxytryptamine
<b>AApoAI</b>	Apolipoprotein A-I
<b>AApoAII</b>	Apolipoprotein A-II
<b>ACD</b>	Amyloidosis cutis dyschromia
<b>AFA</b>	Abdominal fat aspiration
<b>AFib</b>	Fibrinogen $\alpha$ -chain
<b>AGel</b>	Gelsolin.
<b>AL</b>	Amyloid light chains
<b>ALys</b>	Lysozyme.
<b>anti-SAP</b>	Anti serum amyloid p
<b>ASCT</b>	Autologous bone marrow stem-cell transplantation
<b>A<math>\beta</math>2M</b>	Amyloid beta-2 microglobulin
<b>ATTR</b>	Amyloid transports thyroxine and retinol
<b><math>\beta</math>2-M</b>	B2-microglobulin
<b>CA</b>	Cutaneous amyloidosis
<b>CAA</b>	Cerebral amyloid angiopathy
<b>CKs</b>	Cytokeratins
<b>CO<sub>2</sub></b>	Carbon dioxide
<b>CPHPC</b>	Carboxy-pyrrolidin-hexanoyl-pyrrolidine-carboxylic acid
<b>CREST</b>	Calcinosis, raynaud phenomenon, esophageal motility disorders, sclerodactyly, and tanglectasia
<b>CRP</b>	C-reactive protein
<b>DCs</b>	Dendritic cells
<b>DFLC</b>	Difference between involved and uninvolved free light chain
<b>DLQI</b>	Dermatology life quality index.
<b>DMSO</b>	Dimethyl sulfoxide
<b>EAC</b>	External auditory canal
<b>EBV</b>	Epstein-barr virus.
<b>EGCG</b>	Epigallocatechin-3-gallate
<b>ER</b>	Endoplasmic reticulum
<b>FAP</b>	Familial amyloidotic polyneuropathy
<b>FFPE</b>	Formalin fixed, paraffin-embedded.
<b>FISH</b>	Fluorescence in situ hybridization
<b>FLC</b>	Free light chain
<b>FMF</b>	Familial mediterranean fever
<b>FPLCA</b>	Familial primary localized cutaneous amyloidosis
<b>GAGs</b>	Glycosaminoglycans

## *✍ List of Abbreviations*

<b>H&amp;E</b>	Hematoxylin and eosin
<b>HDM</b>	High-dose melphalan
<b>HRQoL</b>	Health-related quality of life
<b>HSPG</b>	Heparan sulphate proteoglycans
<b>Ig</b>	Immunoglobulin.
<b>IHC</b>	Immunohistochemical.
<b>IL</b>	Interleukin
<b>IL31RA</b>	Interleukin-31 receptor alpha
<b>ISA</b>	International society of amyloidosis
<b>kPLCA</b>	Keratinic primary localized cutaneous amyloidosis
<b>LA</b>	Lichen amyloidosis
<b>LECT2</b>	Leukocyte chemotactic factor 2
<b>LMD/MS</b>	Liquid chromatography/ tandem mass spectrometry
<b>LSG</b>	Labial salivary gland
<b>MA</b>	Macular amyloidosis
<b>MCP-1</b>	Monocyte chemotactic protein-1
<b>MENDs</b>	Microscopic epidermal necrotic debris
<b>MMP-1</b>	Metalloproteinases 1
<b>MTZs</b>	Microthermal zones
<b>NA</b>	Nodular amyloidosis
<b>NAFL</b>	Non-ablative fractional laser
<b>NB-UVB</b>	Narrowband ultraviolet B
<b>Nd: YAG</b>	Neodymium-doped yttrium aluminum garnet
<b>NLPCA</b>	Nodular localized primary cutaneous amyloidosis
<b>NT-proBNP</b>	N-terminal pro-brain natriuretic peptide
<b>OSMR</b>	Oncostatin m receptor
<b>OSMR<math>\beta</math></b>	Oncostatin m receptor-beta
<b>PCA</b>	Primary cutaneous amyloidosis
<b>PLCA</b>	Primary localized cutaneous amyloidosis
<b>PUVA</b>	Psoralens ultraviolet A
<b>RNAi</b>	RNA interference
<b>ROS</b>	Reactive oxygen species.
<b>SAA</b>	Serum amyloid a protein
<b>SAP</b>	Serum amyloid p component.
<b>SCT</b>	Stem-cell transplantation
<b>SPF</b>	Sun protection factor
<b>SS</b>	Sjögren's syndrome
<b>ssNMR</b>	Solid-state nuclear magnetic resonance
<b>T<sub>4</sub></b>	Thyroxin
<b>TEM</b>	Transmission electron microscopy



### *✍ List of Abbreviations*

<b>TENS</b>	Tanscutaneous electrical nerve stimulation
<b>ThT</b>	Thioflavin T
<b>TNF</b>	Tumor necrosis factor
<b>TNF-<math>\alpha</math></b>	Tumor necrosis factor alpha
<b>TTR</b>	Transthyretin (transports thyroxine and retinol)
<b>UV</b>	Ultraviolet
<b>UVB</b>	Ultraviolet B

## *List of Figures*

### **List of Figures**

<b>No.</b>	<b>Figure</b>	<b>Page</b>
<b>Figure (1)</b>	Formation of amyloid material	<b>10</b>
<b>Figure (2)</b>	Amyloid in kidney	<b>11</b>
<b>Figure (3)</b>	Amyloid material by EM	<b>12</b>
<b>Figure (4)</b>	Nucleation-dependent fibril formation process	<b>12</b>
<b>Figure (5)</b>	Alignment of oligomers on heparin molecules accelerates the process of fibril formation	<b>19</b>
<b>Figure (6)</b>	Schematic representations of potential mechanisms of amyloid/lipid association	<b>20</b>
<b>Figure (7)</b>	Amyloid in tongue biopsy	<b>28</b>
<b>Figure (8)</b>	Electron micrograph of amyloid fibrils	<b>29</b>
<b>Figure (9)</b>	Immunostains for Amyloid P component in a bone marrow biopsy	<b>31</b>
<b>Figure (10)</b>	Periorbital purpura “ raccoon eyes”	<b>36</b>
<b>Figure (11)</b>	68 year old male with periorbital purpura “ raccoon eyes”	<b>36</b>
<b>Figure (12)</b>	Waxy appearance of intradermal amyloid deposition periorbital	<b>37</b>
<b>Figure (13)</b>	Macroglossia in 68 year old male with ecchymotic lesions	<b>38</b>
<b>Figure (14)</b>	68 year old male with nail changes	<b>38</b>
<b>Figure (15)</b>	Dialysis-related amyloidosis: Bilateral subcutaneous masses on the buttocks	<b>40</b>
<b>Figure (16)</b>	Macular amyloidosis on the upper back	<b>43</b>
<b>Figure (17)</b>	Lichen amyloidosis: hyperkeratotic papules over the extensor surface of the lower limbs with hyper pigmented skin lesions	<b>43</b>
<b>Figure (18)</b>	lichen amyloidosis (Hematoxylin-eosin (H/E) ×200 magnification)	<b>46</b>
<b>Figure (19)</b>	apple-green birefringence under polarized light (Congo red stain ×200 magnification)	<b>47</b>
<b>Figure (20)</b>	Positive CK5/6 staining in the papillary dermal deposits of macular (Immunohistochemistry ×200 magnification)	<b>47</b>
<b>Figure (21)</b>	Waxy yellow–brown plaques located over the right anterior lower leg.	<b>49</b>
<b>Figure (22)</b>	Papulo-nodular lesions on tip of nose	<b>49</b>
<b>Figure (23)</b>	Nodular cutaneous amyloidosis:	<b>50</b>
<b>Figure (24)</b>	Biphasic amyloidosis in 25-year-old Malaysian man with diffuse cutaneous dyspigmentation	<b>52</b>
<b>Figure (25)</b>	Hyperpigmented patches and macules with intermingled hypopigmented macules along with xerosis	<b>53</b>
<b>Figure (26)</b>	HE X100: amorphous eosinophilic deposits (Amyloid) in the papillary dermis	<b>54</b>
<b>Figure (27)</b>	Congo red stain: Amyloid deposits in the papillary dermas showing positive staining	<b>55</b>
<b>Figure (28)</b>	Bullous variant of lichen amyloidosis	<b>56</b>
<b>Figure (29)</b>	Histopathological findings of Bullous variant of lichen amyloidosis	<b>57</b>

## *List of Figures*

<b>No.</b>	<b>Figure</b>	<b>Page</b>
<b>Figure (30)</b>	Bullous variant of nodular amyloidosis	<b>58</b>
<b>Figure (31)</b>	Histopathological findings of Bullous variant of nodular amyloidosis	<b>59</b>
<b>Figure (32)</b>	Symmetrical poikilodermatous lesions in 62-year-old man.	<b>62</b>
<b>Figure (33)</b>	Histology showing subepidermal blister with basal vacuolar changes and superficial perivascular infiltrate consisting mainly of lymphocytes (magnification x 40)	<b>63</b>
<b>Figure (34)</b>	Positive staining with Thioflavin-T in papillary dermis corresponding to hyaline deposits on light Microscopy	<b>63</b>
<b>Figure (35)</b>	Tissue biopsy taken from the EAC tumor of this case.	<b>65</b>
<b>Figure (36)</b>	A 46-year-old uncircumcised male: (A) Well-defined, yellow, waxy, infiltrated plaques. (B) Solitary haemorrhagic papule on the mid-dorsal glans.	<b>66</b>
<b>Figure (37)</b>	A 48-year-old uncircumcised male: (A) Discrete erythematous, waxy papules and nodules on the shaft of the penis. (B) Close-up view.	<b>66</b>
<b>Figure (38)</b>	Amyloid deposition secondary to Bowen's disease	<b>69</b>
<b>Figure (39)</b>	Algorithm for evaluating patients with suspected amyloidosis	<b>72</b>

## **List of Tables**

<b>No.</b>	<b>Tables</b>	<b>Page</b>
<b>Table (1)</b>	Amyloid fibril proteins and their precursors in human	<b>15</b>
<b>Table (2)</b>	Clinicopathological classification of cutaneous amyloidosis based on the causative protein	<b>34</b>
<b>Table (3)</b>	Classification of PLCA based on the type of amyloid precursor	<b>48</b>
<b>Table (4)</b>	Clinical presentation of both kPLCA and NLPCA	<b>51</b>
<b>Table (5)</b>	Comparison between Poikiloderma-like Cutaneous Amyloidosis and ACD	<b>64</b>
<b>Table (6)</b>	Conventional Systemic Chemotherapy Options for AL Amyloidosis	<b>74</b>

## Introduction

Amyloidosis is a generic term referring to abnormal extracellular deposition of heterogenic, misfolded, proteinaceous substances. They are composed of one of a family of biochemically unrelated proteins. These proteins are deposited in the form of insoluble oligomeric and polymeric protein fibrils in various tissues leading to architectural and functional changes of tissue (*Kaltoft et al., 2013 and Bouaity et al., 2014*).

The description of the autopsy of a young man in 1639 by Nicolas Fonteyn, a Dutch physician and poet who lived in Amsterdam, was probably the first patient reported with systemic amyloidosis. The term ‘‘Amyloid’’ was first used in 1838 by Schleiden, a German botanist, to describe the cellulose-like substance of plants (*Touart and Sau, 1998*).

In 1854, Rudolph Virchow was one of the first to use the term amyloid for this amorphous and hyaline change in tissue because of an iodine-staining reaction similar to that of starch (amylon; Greek for origin). Although it is now known that amyloid has nothing to do with starch, the term amyloid is still used today (*Hazenberg, 2013*).

While amyloidosis has been known since the 19th century, it is only within the last few decades that our understanding of it has matured. Although it is common in south east Asia including Japan and Taiwan, it is uncommon in Europe and North America (*Quddus et al., 2014*). The incidence of amyloidosis, although hard to calculate, is estimated to be 8 per million persons per year, in England, and accounting for 85% of all cases in developed countries (*Gertz, 2014*).

Amyloidosis typically appears in middle-age and older individuals and even, occasionally, younger persons. The risk of developing the disease is greater in people who are 50 years and older (*Terrier et al., 2008*), have a chronic infection or inflammatory disease, have a family history of amyloidosis, have multiple myeloma (about 10% of patients with multiple myeloma also develop amyloidosis) and have a kidney disease that requires dialysis for several years (*Steciuk et al., 2002*).

## *✍ Introduction*

Amyloidosis ranges from being localized “ affecting only one tissue or organ” to systemic types. Furthermore, each of these, is subclassified into primary and secondary types (*Bhat et al., 2010*).

However, despite the morphologic similarity in different clinical settings, amyloid is heterogeneous with respect to the nature of the amyloid fibrils. Therefore, classification of amyloidosis has been controversial and difficult for a long time (*Steciuk et al., 2002*).

Although localized cutaneous amyloidosis, in general, is not life threatening condition, it usually presents with itchy, hyperkeratotic papules and plaques. Skin becomes hyperpigmented, lichenified or, in rare variant, may develop waxy nodules that ulcerate and bleed. These disfiguring skin conditions, in addition to itching, may lead to psychosocial and emotional effects that may have a significant impact on quality of life (*Fang et al., 2015*).

However, secondary localized cutaneous amyloidosis type is commonly associated with several skin tumors, both benign and malignant, such as squamous cell carcinoma. Which, increased the mortality rates in cases with localized cutaneous amyloidosis (*Touart and Sau, 1998*).

In contrast to localized amyloidosis, systemic amyloidosis leads to serious life threatening conditions such as: nephritic syndrome, renal failure, liver cell failure, cardiomyopathy, dyspnoea, syncope secondary to orthostatic hypotension, alternating bouts of constipation and diarrhea, splenomegaly, adrenal dysfunction, paresthesiae, peripheral neuropathy and bleeding tendency. These diseases are caused by the progressive deposition of amyloid materials in organs such as: Kidneys, liver, heart, gastrointestinal tract, adrenal glands, nerves and skin (*Hazenberg, 2013*).

Amyloidosis is a tissue-based diagnosis. Biopsy of classical mucocutaneous lesions is the procedure of first choice (*Westermarck, 1995*). However, in the absence of evocative cutaneous lesions, biopsies can be done elsewhere. Abdominal subcutaneous fat, rectal, gingival or renal biopsies are thought to be useful (*Steciuk et al., 2002*).

## ***✍ Introduction***

The available treatments depend on, the amyloidosis type and the organs affected, as well as on the patient's age, condition and personal preference, and the prognosis of amyloidosis and its life expectancy are adversely affected by this factors, too (*Wechalekar et al., 2013*).

While the average survival rate in familial amyloidosis is up to 15 years, the average survival rate is about 12-18 months in primary systemic and myeloma-associated amyloidosis without treatment and only about 6 months for patients with severely impaired heart function. The main cause of death is being cardiac and renal failure, and is linked to degree of plasma cell clonality and marrow infiltration (*Perfetti et al., 1999*). Staging systems and prognostic markers have predominantly focused on cardiac markers (*Kumar et al., 2012*).

Therapy of primary cutaneous amyloidosis (PCA) is not standardized and many treatment modalities have been used with variable success (*Maurelli et al., 2015*). Despite the presence of various therapeutic modalities for primary cutaneous amyloidosis (PCA), none is considered curative or satisfactory (*Bandhlish et al., 2012*), and since the disease runs a chronic course, therapeutic management remains challenging (*Kalkan et al., 2014*).

The treatment of the disease is inadequate, even if there are several alternatives for treatment, either, conventional or novel treatments, these include: topical and systemic treatments (*Love et al., 2008*). But As more data on the pathophysiology of primary localized cutaneous amyloidosis (PLCA) becomes available, new and more targeted treatments can be used for this condition (*Yew and Tey, 2014*).

The precursor-product concept is the current basis of treatment, thereby aiming to decrease the levels of precursor proteins in serum to normal or undetectable values. Future clinical research will be directed at stopping amyloid deposition and increasing amyloid clearance (*Hazenberg, 2013*).

There are various therapeutic modalities for PCA have been proposed for cutaneous amyloidosis that improves the cosmetic appearance of the lesions; Among these modalities, ultraviolet light therapy Such as ultraviolet (UV) A1 phototherapy (*Maurelli et al., 2015*), narrowband ultraviolet B (NB-UVB) phototherapy and

## *✍ Introduction*

photochemotherapy (*Lee et al., 2014*). And physical therapeutic options such as: surgical excision, cryotherapy, dermabrasion (*Wong, 1990*), curettage, electro curettage and electrodesiccation (*Aoki and Kawana, 2009*).

Unfortunately, however, the recurrence rate in certain types of cutaneous amyloidosis is high; thus, the need for new approaches for treatment options (*Norisugi et al., 2014*).

There are many successful laser treatments include: carbon dioxide laser (*Esmat et al., 2015*), pulsed dye laser (*Sawamura et al., 2005*), frequency-doubled Q-switched yttrium aluminum garnet (Nd: YAG) laser (*Liu, 2000*), Recently, fractional ablative 2,940nm Erbium: yttrium aluminum garnet (YAG) laser (*Anitha and Mysore, 2012*) And non-ablative fractional 1,550nm Yttrium/Erbium fiber laser (NAFL) used ,too (*Panchaprateep et al., 2015*).

In addition, this technology shows a clinical outcome equivalent to ablative fractional laser with a more favorable safety profile, especially in darker skin type (*Lee et al., 2014*).

In general, there are no preventive measures for amyloidosis. However, the secondary forms of amyloidosis could be prevented by treating the underlying diseases. In addition, genetic counseling can be beneficial in prevention of familial amyloidosis.